Inventor · disambiguated record
Jane L. Grogan
Also filed as: GROGAN JANE · GROGAN JANE L · GROGAN JANE LOUISE
12 granted patents·33 pending applications·139 citations·filing 2007–2025
91Inventor score
Top patents by PatentIndex Score
45 records- 0196US9499596B2Compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2012·Granted Nov 22, 2016·58 cites·17 claims
- 0295US10626174B2Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitorsGENENTECH INC·Filed 2016·Granted Apr 21, 2020·10 cites·22 claims
- 0395US10611836B2Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2016·Granted Apr 7, 2020·9 cites·12 claims
- 0495US10017572B2Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2016·Granted Jul 10, 2018·19 cites·22 claims
- 0594US10047158B2Anti-TIGIT antibodies and methods of useGENENTECH INC·Filed 2018·Granted Aug 14, 2018·13 cites·30 claims
- 0694US9873740B2Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitorsGENENTECH INC·Filed 2014·Granted Jan 23, 2018·26 cites·13 claims
- 0792US2025108111A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2024·Application pending·0 cites
- 0891US2024307534A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2024·Application pending·0 cites
- 0987US2024082396A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2023·Application pending·0 cites
- 1087US2024417461A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2024·Application pending·0 cites
- 1185US2024166741A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2023·Application pending·0 cites
- 1284US2023226180A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2023·Application pending·0 cites
- 1384US2024117037A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 1484US2023279102A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2022·Application pending·0 cites
- 1583US7923011B2Antibodies to lymphotoxin-alphaGENENTECH INC·Filed 2007·Granted Apr 12, 2011·4 cites·21 claims
- 1682US2022331426A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2022·Application pending·0 cites
- 1781US2023098521A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2022·Application pending·0 cites
- 1878US2025326837A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2025·Application pending·0 cites
- 1977US2022064286A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2021·Application pending·0 cites
- 2076US2021340253A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2176US2021332132A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2275US2021253693A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2021·Application pending·0 cites
- 2375US2021113693A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2473US11390678B2Compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2019·Granted Jul 19, 2022·0 cites·20 claims
- 2572US2020289647A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2672US2021032328A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2020·Application pending·0 cites
- 2771US2020399366A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2869US2024018241A1Anti-cd8 antibodies and uses thereofGENENTECH INC·Filed 2023·Application pending·0 cites
- 2968US2009258013A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2009·Application pending·0 cites
- 3066US2019119376A1Anti-tigit antibodies and methods of useGENENTECH INC·Filed 2018·Application pending·0 cites
- 3166US2018169239A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2018·Application pending·0 cites
- 3263US2017143825A1Methods of treating cancer using tigit inhibitors and anti-cancer agentsGENENTECH INC·Filed 2017·Application pending·0 cites
- 3362US2020155676A1Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonistsGENENTECH INC·Filed 2019·Application pending·0 cites
- 3460US2017145093A1Novel compositions and methods for the treatment of immune related diseasesGENENTECH INC·Filed 2016·Application pending·0 cites
- 3559US8642740B2Antibodies to lymphotoxin-alphaADAMS CAMELLIA W·Filed 2012·Granted Feb 4, 2014·0 cites·12 claims
- 3658US2019169304A1Combination therapy comprising ox40 binding agonists and tigit inhibitorsGENENTECH INC·Filed 2019·Application pending·0 cites
- 3757US8216807B2Antibodies to lymphotoxin-αADAMS CAMELLIA W·Filed 2011·Granted Jul 10, 2012·0 cites·13 claims
- 3857US2020405855A1Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonistsGENENTECH INC·Filed 2020·Application pending·0 cites
- 3956US11739150B2Anti-CD8 antibodies and uses thereofGENENTECH INC·Filed 2020·Granted Aug 29, 2023·0 cites·25 claims
- 4056US8541552B2Antibodies to lymphotoxin-αADAMS CAMELLIA W·Filed 2011·Granted Sep 24, 2013·0 cites·64 claims
- 4156US2021301023A1Diagnostic methods and compositions for cancer immunotherapyGENENTECH INC·Filed 2021·Application pending·0 cites
- 4256US2019194339A1Combination therapy comprising ox40 binding agonists and tigit inhibitorsGENENTECH INC·Filed 2018·Application pending·0 cites
- 4352US2011263451A1Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonistsGENENTECH INC·Filed 2009·Application pending·0 cites
- 4450US2017274073A1Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonistsGENENTECH INC·Filed 2017·Application pending·0 cites
- 4548US2016152720A1Combination therapy comprising ox40 binding agonists and tigit inhibitorsGENENTECH INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →